The investigation of mineral and bone disorder in patients with chronic kidney disease

The investigation of mineral and bone disorder in patients with chronic kidney disease - MBD2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028177

Enrollment

100

Registered

2017-07-12

Start date

2021-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic kidney disease (including renal transplant recipients).

Exclusion criteria

Exclusion criteria: The patients who dose not agree with this study. The patients who are unsuitable for this study.

Design outcomes

Primary

Measure	Time frame
Mortality	—

Secondary

Measure	Time frame
Bone and cardiovascular changes - Fracture, bone mineral density, markers of bone metabolism, X-ray, cardiovascular disease, ABI, PWV, and renal impairment. Related factors - [MBD: Ca, P, PTH, VitD, FGF23, Klotho, and ucOC] [Anemia and iron: CBC, ferritin, TST, hepcidine, and frataxin] [Inflammation: hCRP, IL-6, and TNF alpha] [Oxidative stress: anti-oxidative activity, bilirubin, 8OHdG, and AOPP] [Others: uremic toxins and therapy (VDRA, phosphate binders, calcimimetics, and drugs for treatment of osteoporosis and the others)]. These are evaluated each 6 months.	—

Measure

Time frame

Bone and cardiovascular changes - Fracture, bone mineral density, markers of bone metabolism, X-ray, cardiovascular disease, ABI, PWV, and renal impairment. Related factors - [MBD: Ca, P, PTH, VitD, FGF23, Klotho, and ucOC] [Anemia and iron: CBC, ferritin, TST, hepcidine, and frataxin] [Inflammation: hCRP, IL-6, and TNF alpha] [Oxidative stress: anti-oxidative activity, bilirubin, 8OHdG, and AOPP] [Others: uremic toxins and therapy (VDRA, phosphate binders, calcimimetics, and drugs for treatment of osteoporosis and the others)]. These are evaluated each 6 months.

—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Dep Internal Medicine, Div Kidney and Dialysis

cherry39@hyo-med.ac.jp0798456284

Outcome results